Table 3.
Changes in serum ucOC, Gla-OC, and UGR from baseline after MK-4 supplementation
| Measurement day | Dosage | ucOC (ng/mL) | Gla-OC (ng/mL) | UGR | |||
|---|---|---|---|---|---|---|---|
| Median | Range | Median | Range | Median | Range | ||
| Day 8 | 0 μg/day | 0.29 | (-0.86-3.62) | 0.00 | (-4.13-6.96) | 0.02 | (-0.06-0.18) |
| Day 15 | 300 μg/day | 0.60 | (-8.51-2.05) | 2.28 | (-4.88-13.35) | -0.02 | (-1.16-0.10) |
| Day 22 | 600 μg/day | -0.72 | (-14.30-0.15)* | 3.19 | (-1.71-19.48) | -0.12 | (-1.43-0.01)** |
| Day 29 | 900 μg/day | -2.09 | (-16.13-0.05)** | 1.76 | (-1.04-24.54)* | -0.17 | (-1.52-0.001)** |
| Day 36 | 1500 μg/day | -1.59 | (-15.51-0.65)* | 4.99 | (0.81-31.93)** | -0.16 | (-1.53-0.02)** |
Data are shown as medians with ranges (minimum, maximum) (n = 13). The changes in serum ucOC levels and the UGR decreased significantly from baseline, whereas the changes in Gla-OC levels increased significantly. *P < 0.05, **P < 0.01 (Friedman’s test and the post hoc Bonferroni-adjusted Wilcoxon signed-rank test).